ADVA
27.4.2021 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-MB , the industry’s first ultra-compact outdoor PTP grandmaster clock with multi-band GNSS receiver and integrated antenna. Part of the OSA 5405 Series of smart synchronization devices for indoor or outdoor deployment, the OSA 5405-MB ensures timing accuracy by eliminating the impact of ionospheric delay variation. This empowers communication service providers (CSPs) and enterprises to deliver the nanosecond precision needed for 5G fronthaul and other emerging time-sensitive applications. The multi-band GNSS receiver and integrated antenna enable the OSA 5405-MB to meet PRTC-B accuracy requirements (+/-40nsec) even in challenging conditions. For the first time, the technology is available in an edge timing device with minimal footprint, helping operators achieve unprecedented accuracy and reliability as they roll out wide-spread small cell networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005060/en/
“Our multi-band, multi-constellation GNSS receiver provides an extremely cost-efficient way to achieve PRTC-B UTC-traceable network timing with the levels of accuracy needed for next-generation use cases. By adding this technology to our versatile, small-form-factor OSA 5405 Series, we’re offering a route to precision synchronization at the network access without significant investment,” said Gil Biran, general manager, Oscilloquartz, ADVA. “A ruggedized design and minimal visibility make our OSA 5405-MB easy to install in almost any outdoor location. With the power to compensate for ionospheric delay variations and provide resilience against jamming and spoofing, our compact edge solution really is the key to 5G synchronization.”
The OSA 5405 Series is a uniquely versatile timing solution ideal for deployment deep in urban canyons, precisely where the most advanced end applications require stringent synchronization. With its small form factor, the OSA 5405-I indoor variant can be positioned on windows to avoid multipath signal interference. Offering both electrical and optical interfaces and featuring cost-effective Ethernet cabling, the OSA 5405 Series avoids the archaic and expensive RF feeds of traditional GNSS installations by integrating an antenna, GNSS receiver and PTP grandmaster in a single device.
Now with multi-band GNSS technology, the OSA 5405-MB also protects against timing inaccuracies caused by ionospheric disturbance. By receiving GNSS signals in two frequency bands and using the differences between them to calculate and compensate for delay variation, the OSA 5405-MB eliminates inaccuracy and ensures ultra-precise synchronization whatever the space weather conditions. It can also work with up to four concurrent GNSS constellations (GPS, GALILEO, GLONASS and BEIDOU), increasing the number of observable satellites in urban canyons. A comprehensive set of Syncjack™ PTP and GNSS jamming and spoofing monitoring features in combination with ADVA’s Ensemble Controller and Sync Director assures highest synchronization quality and provides transparency for simple operation of even very large synchronization networks. The OSA 5405-MB also offers network-delivered timing backup to further mitigate GNSS vulnerabilities and make synchronization more robust and resilient.
“Highly accurate timing is becoming more critical every year. In CSP infrastructure, power utilities, broadcast and enterprise networks across most industries, precision synchronization that meets tight PRTC-B specifications is essential. The OSA 5405-MB is capable of providing different PTP profiles as well as NTP directly out of the smart antenna with no compromise on accuracy,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “With its multi-band receiver, our new OSA 5405-MB delivers PRTC-B levels of synchronization accuracy. Small, lightweight, low-power and versatile, it can be deployed almost anywhere and will perform perfectly even under extreme conditions. What’s more, its Syncjack™ PTP and GNSS assurance capabilities ensure accurate, real-time monitoring of timing quality.”
Further information on the OSA 5405-MB is available in these slides: https://adva.li/osa-5405-mb-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005060/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
